Fierce JPM Week 2025

With innovation in new modalities driving increased complexity in the pharmaceutical pipeline, there is increasingly urgent need to deliver speed, quality, cost-efficiency and improved environmental footprint in pharmaceutical manufacturing. CDMOs are innovating across a number of areas to deliver this transformation – including by employing artificial intelligence, bringing tangible use cases to a promising technology.

In this session, Mike Riley, CEO of Veranova and David Shrier, CEO and Co-Founder of Phorum AI, will discuss a novel collaboration between their companies and will discuss how innovations in AI can unlock the potential of great scientific teams to create exponential improvements - 10x or even 100x - in the efficiency of how pharmaceuticals are produced.

This panel will explore how agentic AI and human intelligence will transform drug development, from early-stage discovery and target identification to optimizing clinical trials and advancing personalized treatments. Key topics include AI’s role in accelerating research, improving trial design, and enhancing patient recruitment. The discussion will also address the challenges of understanding complex biology, ensuring data quality, and fostering cross-industry collaboration. By harnessing collective intelligence, the panel will highlight how these technologies can drive innovation, efficiency, and personalization across the drug development pipeline by harnessing collective intelligence.